SCHEMBL5142976

SCHEMBL5142976

CC(NS(=O)(=O)c1ccccc1)C(Cc1ccc(Cl)cc1)Oc1ccc(C#N)cc1

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 19/20 0.61
CNR2 P34972 15/20 0.61
ADAMTS4 O75173 1/20 0.47
MMP13 P45452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5585077 0.92 CNR1 (0.53) CNR1CNR2
SCHEMBL5585088 0.89 CNR1 (0.53) CNR1CNR2
SCHEMBL5177950 0.86 CNR1 (0.48) CNR1CNR2MMP13
SCHEMBL5145180 0.82 CNR1 (0.47) CNR1CNR2
SCHEMBL5147300 0.82 CNR1 (0.59) CNR1CNR2ADAMTS4MMP13
SCHEMBL14512665 0.82 CNR1 (0.48) CNR1CNR2ADAMTS4
SCHEMBL5145056 0.80 CNR1 (0.53) CNR1CNR2
SCHEMBL5584867 0.80 CNR1 (0.50) CNR1CNR2
SCHEMBL14512668 0.76 CNR1 (1.00) CNR1CNR2
SCHEMBL5145238 0.76 CNR1 (1.00) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663113-A4 SUBSTITUTED SULFONAMIDES MERCK & CO INC (US) 2007-06-13 EP claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US claimed
EP-1663113-A2 SUBSTITUTED SULFONAMIDES Merck & Co., Inc. (US) 2006-06-07 EP claimed
WO-2005027837-A2 SUBSTITUTED SULFONAMIDES MERCK & CO., INC. (US) 2005-03-31 WO claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105914-A1 Substituted sulfonamides CNR2, CNR1, FAAH CNR1 2/4885CNR2 1/4885ADAMTS4 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.